NCI Launches Two New Efforts to Recruit Patients Into Clinical Trials

A new biomarker, KIM-1, has the potential to show outcomes and response for patients with renal cell carcinoma.

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Data from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.

Stereotactic body radiotherapy is less expensive and has demonstrated an improved safety profile vs immunotherapy and tyrosine kinase inhibitors.

Data from a Q-TWiST analysis of the LITESPARK-005 trial provide additional evidence for the use of belzutifan in those with advanced renal cell carcinoma.